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ABSTRACT We report a combined quantum mechanics/molecular mechanics (QM/MM) study to determine the protein-ligand
interaction energy between CDK2 (cyclin-dependent kinase 2) and ﬁve inhibitors with the N2-substituted 6-cyclohexylmethox-
ypurine scaffold. The computational results in this work show that the QM/MM interaction energy is strongly correlated to the
biological activity and can be used as a predictor, at least within a family of substrates. A detailed analysis of the protein-ligand
structures obtained from molecular dynamics simulations shows speciﬁc interactions within the active site that, in some cases,
have not been reported before to our knowledge. The computed interaction energy gauges the strength of protein-ligand inter-
actions. Finally, energy decomposition and multiple regression analyses were performed to check the contribution of the elec-
trostatic and van der Waals energies to the total interaction energy and to show the capabilities of the computational model to
identify new potent inhibitors.
INTRODUCTION
The cyclin-dependent kinases (CDKs) play an essential role
in regulating eukaryotic cell-cycle progression (1). These
protein kinases are generally categorized into G1, S, and G2
phase regulators because they are present at various check-
points in the cell cycle (2). As their name suggests, the CDKs
are dependent on larger proteins known as cyclins for acti-
vation. Only as a complex can these proteins regulate cell
growth and DNA synthesis properly. Partial activation oc-
curs upon binding of these positive regulatory subunits; com-
plete activation requires phosphorylation of the CDK subunit
by the CDK-activating kinase at the conserved threonine
residue. The CDK considered in this study is CDK2, which
combines with cyclin E at an S-phase checkpoint known as
the restriction point. In the same way, the completion of the
S-phase depends on a complex of CDK2 and cyclin A (2).
The activity of the CDK-cyclin complex can be reduced
by at least two major mechanisms: the phosphorylation of the
CDK subunit at inhibitory sites and the binding of the spe-
cialized protein inhibitors known as CKIs or CDK inhibitors.
These inhibitors compete with ATP (adenosine 59-triphos-
phate) for binding to the CDK active site. However, in some
cancer cells it has been shown that the CKIs are underex-
pressed, and medicinal chemists have made numerous efforts
to replace the CKIs with synthetic inhibitors (3). Considerable
progress has been made in the identiﬁcation of pharmaco-
logic agents targeting the CDKs (4). A large number of ATP-
competitive inhibitors from a variety of chemical classes
have been identiﬁed (2,5–7). Among noteworthy attempts to
produce such inhibitors are a series of compounds based
on O6-cyclohexylmethylpurine or NU2058 (8) (see Fig. 1),
which are competitive inhibitors of both CDK1 and CDK2
with respect to ATP. They also display good selectivity over
CDK4 (9). Several authors, with the aid of iterative structure-
based drug design, have carefully explored this scaffold. In
this way, it has been possible to identify three kinds of char-
acteristic interactions for this class of compounds within the
active site of some CDKs. The ﬁrst is the presence of the
triplet of hydrogen bonds formed between the different
tested compounds and the hinge region in CDK1 and CDK2.
This feature induces a different orientation of these com-
pounds inside the active site of the enzyme with respect to
other inhibitors such as ﬂavopiridol and olomoucine, and of
course it has direct consequences for enzyme and cell growth
inhibition (8). A second characteristic for this family of com-
pounds is that optimum binding occurs with a moderately
sized aliphatic O6 substituent that tightly packs against the
hydrophobic patch presented by the glycine loop, centered
on Val-18—an interaction promoted by the conformational
constraints imposed in a cyclohexylmethyl or cyclohexenyl-
methyl ring.
Thus, the parent compound O6-cyclohexylmethylguanine
(NU2058) is the preferred starting point for exploring other
areas of the kinase active site (10). The third characteristic
kind of interactions are those established with the so-called
‘speciﬁcity surface’; this is with residues that lie outside the
highly conserved ATP binding site cleft (11,12). Sequence dif-
ferences between the different members of the CDK family
exist in this region, and targeting them may afford selectivity.
For example, CDK2 residues His-84, Gln-85, and Lys-89 are,
respectively, an aspartate, a glutamine, and a threonine in
CDK4. Studies on olomoucine (13) and roscovitine (14) have
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shown that large gains in potency, in addition to speciﬁcity,
are possible by targeting this ‘speciﬁcity surface’. Structural
analysis had indicated that an aromatic ring at the N2 posi-
tion of NU2058 would improve inhibitory activity against
CDK1 and CDK2 (9). This was found to be the case with the
resulting compound produced by maintaining the speciﬁcity
for the inhibition of CDK1/2 over CDK4. Additional po-
tency is conferred by the presence of a group capable of
donating a hydrogen bond at the 49-position in the aromatic
ring. The resulting compound of all these previous structural-
based investigations is NU6102 (compound 3 (Cp3) in Fig.
1). This inhibitor is selective and one of the most active
CDK2 inhibitors described so far (9,15). Regardless of this
signiﬁcant progress in the structural-activity relationships for
this kind of anticancer compounds, there remains the need to
ﬁnd a broader spectrum inhibitor that can, for example, se-
lectively inhibit CDK1, CDK2, CDK4, and CDK6 at low
nanomolar IC50 concentrations. The investigation of CDK2-
ligand interactions can provide further insight for developing
new compounds that are still required to achieve selective cy-
totoxicity and valuable anticancer activity.
Supplementary to a tremendous amount of experimental
work, a few theoretical studies on CDKs, based on classical
and quantum mechanical calculations, have also been
reported in the literature. For instance, Cavalli et al. have
developed force ﬁeld parameters based on quantum chemical
calculations on a relevant model system for simulating the
binding of ATP to CDKs (16). Molecular dynamics (MD)
simulation with the newly calculated parameters showed that
CDK1 should be dynamically more stable than CDK2, im-
plying that differences in protein structure ﬂexibilities among
CDKs should be considered in designing their selective in-
hibitors. More recent computational studies on CDK2 by
Sims et al. have established a binding free energy model for
CDK2 inhibitors within the framework of the continuummodel
for the solvent (17). This approach proved to be successful in
reproducing the relative inhibitory activities of ﬂavopiridol
analogs. On the basis of the validated utility of the computa-
tional approach, they suggested new putative inhibitors that
were predicted to be more potent than the lead compound. In
a later work, these same authors implemented the previously
developed, continuum solvent-based charge optimizationmodel
with a simple, quadratic programming algorithm and the
UHBD Poisson-Boltzmann solver (18). This method allowed
them to compute the best set of point charges for a ligand or
ligand region based on the ligand and receptor shape and the
receptor partial charges by optimizing the binding free energy
obtained from a continuum-solvent model (18). However,
there are several limitations to such a model of binding free
energy (17,19,20). In their particular case, they applied a ﬁxed
conformation model that assumes that the ligand and receptor
undergo no conformational change upon binding.
Consideration of protein ﬂexibility is indispensable for
a critical evaluation of ligand-binding afﬁnity (21–24), espe-
cially here because the conformational plasticity of the cat-
alytic domain is a hallmark of protein kinases (25). As ever,
a tradeoff between accuracy and computational expense is
unavoidable. Empirical scoring functions designed for the fast
estimation of binding afﬁnities for high-throughput virtual
screening often neglect conformational ﬂexibility of the pro-
tein, entropic effects, and desolvation during the binding
process (26). At the other end of the accuracy range are tech-
niques based onMD simulations in explicit solvent that make
use of free energy perturbation, thermodynamic integration,
and linear interaction energy methods (27,28). Given sufﬁ-
cient sampling, MDmethods can be used to calculate the free
energy of protein/ligand binding with high accuracy, includ-
ing all entropic and solvent effects as well as receptor
ﬂexibility. The main problem associated with this methodol-
ogy is the computational effort required to adequately sample
the full conﬁgurational space and also to parametrize each
new ligand essayed. Here we investigate a strategy to over-
come these two computational bottlenecks based on the use of
combined quantum mechanical/molecular mechanical (QM/
MM) methods. These methods are now widely used for the
analysis of enzymatic reactions (29–31). In combinedQM/MM
FIGURE 1 Structures of the N2-substituted O6-cyclohexylmethylguanine
derivatives of Hardcastle et al. (15). Numbering of atoms in the purine
moiety is also displayed.
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methods, the ligand/substrate species is treated explicitly
by a QM model (32–35), avoiding the derivation of param-
eters for each new ligand.
The protein and solvent environment is represented byMM
force ﬁelds, which are computationally efﬁcient. Treating the
ligand quantum mechanically and the protein molecular
mechanically has the additional advantage of the inclusion of
ligand polarization upon binding. Besides these two impor-
tant computational aspects, there exists an additional point
that is worth mentioning. With a QM deﬁnition of the ligand,
a better treatment of its accessible conﬁgurations could be
expected, no matter what kind of functional group it may
contain. It is important tomention that some functional groups
are very difﬁcult to parametrize, in the MM approach, when
effects like electronic delocalization are present. There are
some recent computational studies that successfully applied
the combined QM/MMmethod to the study of protein-ligand
interactions in the HIV-1 protease system (36) and in the
trypsin system (37). In this work we propose an additional
step in the use of QM/MMmethod for inhibitors analysis. We
show below that theQM/MM interaction energy can be safely
used to predict the biological activity of a particular inhibitor,
at least when comparing within a given family of compounds.
As mentioned before, binding free energies are computation-
ally expensive, whereas interaction energies can be much
more easily obtained. In this way two of the largest incon-
veniences in the use of MD simulations, the need of re-
parametrization for each new compound and the extensive
sampling of different states required to evaluate free energy
changes, can be conveniently overcome. In particular, wewill
show the effectiveness of the proposed strategy for the set of
CDK2 inhibitors presented in Fig. 1.
METHODS
Simulations
All simulations were performed using the DYNAMO software package (38).
The initial coordinates for the QM/MM calculations were taken from the
x-ray crystal structure of the Nu6102 inhibitor bound to the fully activated
Thr-160-phosphorylated CDK2-cyclin A complex (T160pCDK2-cyclinA)
(Protein Data Bank code 1H1S) (9). The amino acids Arg-297 and Leu-298
were added to the CDK2 subunit of the initial crystal structure with the aid
of the program Molden (39) to have a complete protein system. To mimic the
aqueous environment, an equilibrated water box with sides of 79.5 A˚, centered
on the mass center of each inhibitor, was used to solvate the T160pCDK2-
cyclinA-ligand system. Amino acid residues and water molecules placed more
than 25 A˚ away from the center of the box were ﬁxed during the simulations.
The inhibitors inside the ATP active site were chosen to be the QM subsystem,
described at the AM1 level (40), whereas the rest of the T160pCDK2-cyclinA
complex and the water molecules of crystallization and those belonging to the
solvent box constitute the MM subsystem were described using the optimized
potential for liquid simulations (OPLS) force ﬁeld (41) and the ﬂexible TIP3P
potential (42,43), respectively.
There are no bonds between the QM and the MM subsystems; so we do
not need to consider any special treatment to complete the valence of the
frontier quantum atoms (44). The remaining systems studied were obtained
from this initial model by simply deleting and replacing a few atoms of the
inhibitor Nu6102 (see Fig. 1). Initially, the hydrogen atoms of the system
were relaxed using the conjugate gradient subroutine implemented in the
DYNAMO program (45). Then the full system was minimized up to a
gradient tolerance of 1.0 kJ/mol. Subsequently the system was heated up to
300 K by a sequence of MD simulations. Afterwards the system was further
equilibrated during additional 100 ps using the NVT ensemble at 300 K. The
production run consisted of anMD simulation of 250 ps. In all cases we used
a time step of 1 fs to solve the equations of motion and a switched cutoff
distance of 13.5 A˚. One protein-ligand conﬁguration was saved each 15 time
steps for a posteriori energetic and structural analysis. This procedure was
applied to the ﬁve inhibitors presented in Fig. 1.
Energy decomposition
The energy for a QM/MM system can be obtained as
E ¼ ÆCjHˆ0jCæ1 ÆCjVˆQM=MMjCæ1EMM; (1)
where Hˆ0 is the in vacuum Hamiltonian for the selected QM method, C is
the polarized wave function (that is, the wave function obtained in the pres-
ence of the MM ﬁeld), EMM represents the force ﬁeld energy, and VˆQM=MM is
the coupling operator between the QM and MM subsystems and includes an
electrostatic and a van der Waals term. Eq. 1 can be written in a different
form to deﬁne the QM/MM interaction energy. In our partition scheme the
total energy is written as the sum of the in vacuum energy of the QM
subsystem, the QM/MM interaction energy, and the MM energy (46):
E ¼ ÆC0jHˆ0jC0æ1 ½ÆCjHˆ0jCæ ÆC0jHˆ0jC0æ
1 ÆCjVˆQM=MMjCæ1EMM; (2)
where C0 stands for the unpolarized (gas phase) wave function of the QM
subsystem. The ﬁrst term on the right side represents the gas phase energy of
the quantum subsystem (usually the ligand), the second term (the one inside
the brackets) the polarization energy of the quantum subsystem wave func-
tion, and the third one the QM/MM interaction energy with the polarized
wave function. The sum of these two last terms is the total QM/MM inter-
action energy. This energy can be further decomposed considering that the
coupling operator between the QM and MM subsystems (VˆQM=MM) includes
an electrostatic and a van der Waals term. This last contribution is usually













where Rij is the distance between the QM and MM interaction centers and eij
and sij are the Lennard-Jones parameters. As this expression does not in-
volve electronic coordinates, this energy term does not need to be included
in the SCF evaluation of the QM subsystem wave function.
The interaction energy can, then, be calculated as the energy difference
between the full QM/MM system and the separated QM and MM sub-
systems. Taking into account that in nonpolarizable force ﬁelds the MM
energy exactly cancels out, we can write
EQM=MM ¼ E ÆC0jHˆ0jC0æ EMM; (4)
which means that in vacuo single point energy calculation must be carried
out for given nuclear conﬁgurations of the quantum atoms along the tra-
jectory and then subtract this energy and the MM energy to the full QM/MM
potential energy. Note that according to our deﬁnition of the polarization
energy (term inside the brackets in Eq. 2) as the gas phase energy difference
between the polarized and unpolarized wave functions, this is a positive
contribution. A different energy decomposition scheme was used in Hensen
et al. (36). Finally, it is also worth noting that the set of conﬁgurations over
which the average is carried out depends on the temperature at which the
simulation is performed. So, the average interaction energy is in fact tem-
perature dependent.
432 Alzate-Morales et al.
Biophysical Journal 92(2) 430–439
RESULTS AND DISCUSSION
In this section we ﬁrst present the structural features of each
of the CDK2-inhibitor complexes. Then we analyze the inter-
action energies and the relationship to the biological activity
(measured as IC50). Both geometrical data and energy terms
have been averaged during the production run, and the stan-
dard deviation is provided as a number in parenthesis ac-
companying the average value.
Ligand-active site interactions: compounds 2
(Nu6094) and 25
It is well known that several compounds such as purvalanols
(47) and indirubins (48,49) pack aromatic moieties with the
speciﬁcity surface of CDK2. Compound 2 (Cp2) was ini-
tially synthesized taking this property into account. Then,
according to Davies et al., the aniline group of Cp2 projects
out of the adenine site through a largely hydrophobic tunnel
constituted by the side chains of Phe-82 and Ile-10 and packs
against the kinase surface, forming a p-p stacking interac-
tion with the peptide backbone between Gln-85 and Asp-86
(9). The ﬁnal structure obtained from the MD simulations is
shown in Fig. 2. As a common feature for the ﬁve inhibitors
analyzed here, a triplet of hydrogen bonds is formed between
the purine ring and the hinge region of CDK2: NH-9 acts as a
hydrogen-bond donor to the backbone carbonyl group of
Glu-81, and N-3 and 2-NH2 accept and donate a hydrogen
bond to the backbone carbonyl and amide groups of Leu-83,
respectively. The averaged distances for the triplet of hy-
drogen bonds for each ligand are given in Table 1, being the
values quite similar for the ﬁve compounds. From the
analysis of geometrical data from the MD simulation, we
have found other weak interactions between the Cp2 and the
protein, the C-Hp weak interaction between the a-carbon
hydrogen of Gln-85 and the center of the aniline ring of
ligand being the most signiﬁcant. The averaged distance
from the hydrogen atom to the centroid of the ring is;2.90 A˚.
There exists another weak interaction of the type C-HO¼C
between one of the aniline ring hydrogens and the carboxylate
group of Asp-86 (Cp2 Ph-H to Asp-86 OD2¼ 3.35 A˚ (60.49
A˚)). It is worth mentioning that the side chain of Lys-89 is
tilted away from the aniline ring of the ligand. The NH13 group
of this residue makes a stabilizing hydrogen bond with the
carbonyl side-chain group of Gln-85 (Fig. 2).
The potencies of the 49-substituted C2-anilino-O6-cyclo-
hexylmethyl-purine series were evaluated by Hardcastle et al.
(15). They found that 49-hydroxy substitution in this series
generated compound 25 (Cp25) which was substantially
more potent than the parent aniline Cp2. This result sug-
gested that there was a hydrogen-bond acceptor in the region
of the protein accessed by the 2-anilino group. An obvious
candidate was the Asp-86 residue. The data obtained from
our MD simulations (see Fig. 3) show the hydroxyl group
of Cp25 interacting with the carboxylate moiety of Asp-86
via a water-mediated hydrogen bond (Cp25 O-TIP3-Asp-86
OD2 ¼ 3.29 A˚/2.62 A˚ (60.42 A˚/60.10 A˚)). This result is in
agreement with the crystallographic data reported by Davies
et al., although the hydrogen-bond distances are different
from those quoted by them (9). We observed two additional
hydrogen bonds between the hydroxyl group and the Lys-89
residue. One of them is formed between the oxygen atom of the
hydroxyl group and the NH13 group of Lys-89 (Cp25 O-Lys-89
NZ ¼ 3.79 A˚ (60.66 A˚)). The hydroxyl group also interacts
with Lys-89 via a water-mediated hydrogen bond (Cp25
O-TIP21-Lys-89 NZ ¼ 3.31 A˚/2.94 A˚ (60.37 A˚/60.51 A˚)).
TABLE 1 Hydrogen-bond-averaged distances (A˚) between the purine ring of each ligand and the hinge region of the CDK2 active site
Fragment Cp 2 Cp 25 Cp 3 Cp 9 Cp 7
Glu-81 C¼O—H-N9 1.96 (60.16) 1.88 (60.14) 1.92 (60.15) 1.90 (60.15) 1.91 (60.15)
Leu-83 N-H—N3 2.49 (60.25) 2.62 (60.21) 2.46 (60.21) 2.60 (60.23) 2.72 (60.30)
Leu-83 C¼O—H-N2 1.94 (60.17) 1.94 (60.17) 1.90 (60.17) 1.97 (60.19) 2.01 (60.21)
The values in parentheses correspond to the standard deviations.
FIGURE 2 Snapshot of the CDK2-Cp2 structure. Selected residues of the
CDK2 active site are shown in licorice representation, and Cp2 is presented
in ball-and-stick representation, with carbon atoms colored in yellow
(CDK2) and cyan (inhibitor). The hydrogen bonds are depicted as black
dashed lines.
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Compound 3 (Nu6102)
This compound presents a particular interaction pattern within
the active site of CDK2 due to the presence of the sulfon-
amide group. Hardcastle et al. reported that this compound
interacts with Asp-86 through the NH2 group of the sulfon-
amide, which donates a hydrogen bond to the side-chain
oxygen of Asp-86 (Cp3 N26 to Asp-86 OD2 ¼ 2.9 A˚) and
through one sulfonamide oxygen that accepts a hydrogen
bond from the backbone nitrogen of Asp-86 (Cp3 O24 to
Asp-86 NH ¼ 3.1 A˚) (15). They have further suggested that
the high activity of Cp3 is due to the two additional H-bonds
formed with Asp-86. However, we have found that the in-
teractions formed for this compound inside the active site of
CDK2 are different from those reported before. A represen-
tative snapshot of this protein-inhibitor complex as obtained
in our MD simulation is provided in Fig. 4. In addition to the
triplet of hydrogen bonds established with the hinge region,
reported in Table 1, we have found other CDK2-Cp3 hy-
drogen bonds. The NH2 group of the sulfonamide donates a
hydrogen bond to each of the side-chain oxygen atoms of
Asp-86 (Cp3 O2S-N to Asp-86 OD1 ¼ 3.78 A˚ (60.40 A˚)
and Cp3 O2S-N to Asp-86 OD2 ¼ 3.38 A˚ (60.45 A˚)). One
sulfonamide oxygen atom accepts a hydrogen bond from the
NH13 side-chain group of Lys-89 (Cp3 S¼O to Lys-89 NZ¼
2.80 A˚ (60.15 A˚)).
According to Davies et al. (9), although the Cp3 aniline
group packed closely with the speciﬁcity surface, the sulfon-
amide group did not form the proposed hydrogen bond with
Lys-89. We have found that this interaction does occur and
that the sulfonamide group is positioned in a geometry that
facilitates this unreported protein-ligand hydrogen bond.
Finally, the last hydrogen-bond interaction found for this
compound, and not yet reported, occurs between the other
sulfonamide oxygen atom and the backbone carbonyl group
of residue Ile-10. The hydrogen bond is this time mediated
by a water molecule from the solvent water box (Cp3 S¼O-
TIP526-Ile-10 C¼O ¼ 3.07 A˚/3.39 A˚ (60.66 A˚/60.76 A˚)).
Compounds 9 and 7
These compounds belong to the nonaromatic series studied
by Hardcastle et al. (15). They proved to be more potent
CDK1 and CDK2 inhibitors than the parent compound
Nu2058 (8), and both form a triplet of hydrogen bonds
within the CDK2 ATP binding site (see Table 1). Compound
9 (Cp9) is the isopropyl N2-monosubstituted derivative of
the series studied and forms a weak C-Hp interaction with
the peptide backbone between Gln-85 and Asp-86 through
one of the isopropyl hydrogen atoms. The protein-ligand
complex is shown in Fig. 5. The isopropyl group establishes
a nonpolar interaction with the side chain of Ile-10 and a
weak hydrogen-bond interaction of the type C-HO¼C,
with one of the side-chain oxygens of Asp-86 (Cp9
isopropyl-H to Asp-86 OD2 ¼ 3.78 A˚ (60.49 A˚)). On the
other hand, compound 7 (Cp7) is the methyl N2-monosub-
stituted derivative in this series. This compound establishes
the typical triplet of hydrogen bonds with the hinge region of
CDK2 (Table 1) and a nonpolar interaction with the side
chain of residue Ile-10 (Fig. 6). The lack of a bulky group in
this ligand, like the isopropyl in Cp9, causes a diminished
interaction with Ile-10.
FIGURE 3 Snapshot of the CDK2-Cp25 structure. Representation is made
as in Fig. 2.
FIGURE 4 Snapshot of the CDK2-Cp3 structure. Representation is made
as in Fig. 2.
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Analysis of interaction energies
Averaged interaction energies for each of the inhibitors with
CDK2, together with their electrostatic and van der Waals
components, are reported in Table 2. The biological activity
is also provided as the common logarithm of IC50 (15). The
potency of each ligand is obviously related to its binding free
energy but assuming that, within a family of compounds,
solvation/desolvation energies, enzyme deformation energy,
and entropic changes are proportional to the magnitude of the
interactions established between the inhibitor and the protein,
one may then express the activity as a function of the inter-
action energy:
LogIC50 ¼ aDEQM=MM1b: (5)
The result of a least-square ﬁt of Eq. 5 using data of Table
2 is shown in Fig. 7. The high value obtained for the cor-
relation coefﬁcient (R ¼ 0.96) makes us conﬁdent in our
simulation procedure. In addition, it clearly indicates that in-
teraction energies can be safely used as a predictor of the
biological activity of a given inhibitor, at least when com-
paring them with a series of compounds belonging to the
same family. The interest in this kind of correlations is ob-
vious considering the large difference in computational ef-
fort needed to evaluate interaction energies or binding free
energies. The use of QM/MM procedures has the additional
advantage of avoiding extensive reparametrization for each
new ligand considered in the study. An interesting practical
conclusion can also be drawn from the study of the quality of
the ﬁt as a function of the length of the sampling used in the
evaluation of the interaction energies. If instead of using the
full 250-ps simulation to average the interaction energy, one
averages them only over the last 100 ps, the correlation co-
efﬁcient is slightly reduced up to 0.95, indicating that the sam-
pling, and then the computational effort, could be reduced
without a signiﬁcant loss of quality.
It is also interesting to relate the different interaction
energies and their decomposition to the structural features of
the different inhibitor-protein complexes. It can be seen from
Table 2 that the magnitude of the electrostatic contribution is
FIGURE 6 Snapshot of the CDK2-Cp7 structure. Representation is made
as in Fig. 2.
FIGURE 5 Snapshot of the CDK2-Cp9 structure. Representation is made
as in Fig. 2.
TABLE 2 Averaged QM/MM interaction energies and its components (kcal/mol) for the CDK2 inhibitors studied
Compound 2 Compound 25 Compound 3 Compound 9 Compound 7
Interaction energy 73.4 (62.9) 86.2 (63.5) 124.5 (68.2) 70.2 (64.0) 65.5 (63.1)
Electrostatic energy 17.5 (62.4) 30.2 (63.4) 65.8 (69.0) 23.4 (63.5) 22.8 (63.3)
vdW energy 55.9 (62.2) 56.1 (62.5) 58.6 (63.0) 46.8 (62.4) 42.7 (62.4)
Log IC50 0.013 1.161 2.268 0.079 0.699
Biological activities are reported as the common logarithm of IC50 (micromolar) (15).
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similar for compounds 9 and 7, as result of the very similar
hydrogen-bond interactions presented by these ligands with
the hinge region in CDK2. The van der Waals interaction
energy is different for these two compounds due to the dif-
ference in the substitution pattern at the N2 position of the
purine ring. The main consequence arising from this differ-
ence is that Cp9 bears a more polarizable isopropyl group at
the N2 position, thereby promoting a more favorable inter-
action with the Ile-10 residue than Cp7, which bears a methyl
group at that position. This example clearly shows that the
activity can be improved by the optimization of the van der
Waals interactions. The opposite is found for Cp2 and
Cp25. These compounds show similar van der Waals con-
tributions to the interaction energy, and their electrostatic
energy values are different (Table 2). The difference in the
electrostatic energy for these two compounds can be attrib-
uted to a signiﬁcant interaction between the 49-substituent
group in the phenyl ring of the aniline group and some amino
acids in the speciﬁcity surface. For Cp2, the larger van der
Waals energy contribution (in absolute value), when compared
to the corresponding values for Cp9 and Cp7, is in agreement
with the expected interaction pattern with the speciﬁcity surface
at the active site of CDK2. That means that the presence of an
aniline ring in the C-2 position of the purine ring is more fa-
vorable than a nonaromatic group like methyl (Cp7) or propyl
(Cp9).
The electrostatic energy component for Cp2 is smaller, in
absolute value, than the corresponding values found for Cp7
and Cp9. This can be attributed to a less favorable interaction
between the purine ring of this compound and the hinge re-
gion of CDK2. However, this low contribution is compen-
sated for by an increase in the van der Waals interaction
energy. Cp25, on the other hand, shows an increase in the
electrostatic energy component due to the hydrogen-bond
interactions formed by the OH group in the 49-position of
the aniline ring with the residues of the speciﬁcity surface of
the enzyme. It is also interesting to mention that Cp3 is the
only one that has an absolute value of the electrostatic energy
component greater than the van der Waals term. This result
can be attributed to the multiple hydrogen-bond interactions
that this compound can establish with residues Asp-86, Lys-89,
and Ile-10, which are present in the CDK2 speciﬁcity sur-
face. Comparing the van der Waals energy value for this com-
pound with those evaluated for Cp2 and Cp25, we can
conclude that the van der Waals energy component has a
similar weight in these compounds, but this energy compo-
nent is slightly improved due to the interaction formed with
the amino acids in the speciﬁcity surface and, consequently,
to the more effective packing with the hydrophobic surface
within the active site of the CDK2. The ﬁnal result for Cp3 is
an improved interaction and then a larger inhibitor activity.
Finally, to evaluate if our interaction energy partition is a
reliable model to represent the interaction between each li-
gand and the active site of CDK2, a two-variable regression
analysis was performed. The two independent variables are
the electrostatic energy and the vdW energy components,
and the dependent variable is the logarithm of the IC50 inhibi-
tory concentration obtained from the experiments. The re-
sulting regression equation is
LogIC50 ¼ g1a  DEelec1b  DEVdW
¼ 4:9731 0:038  DEelec1 0:082  DEVdW; (6)
where DEelec and DEVdW, are the electrostatic and the van der
Waals interaction energy components, respectively. The stan-
dard deviation values for the parameters g, a, and b involved
in the equation above are 1.46, 0.011, and 0.031, respec-
tively. This equation can be used to predict LogIC50 values,
which are quoted in Table 3. We have plotted these predicted
LogIC50 values against the experimental LogIC50 values.
The comparison yields a very good correlation coefﬁcient
R ¼ 0.976 (see Fig. 8). Interestingly, Eq. 6 displays quite
different values for the slopes associated with the electro-
static and van der Waals interaction energies, suggesting that
an improvement of this last contribution could be more effec-
tive, in terms of inhibition, than a similar energetic improve-
ment in the electrostatic component. Obviously, another
question is that obtaining differences in the van der Waals
interaction energy may be more difﬁcult than for the elec-
trostatic part, as suggested by the ranges covered by these
FIGURE 7 Graph of LogIC50 versus QM/MM interaction energy (kcal/
mol) for the ﬁve N2-substituted O6-cyclohexylmethylguanine derivatives
studied and equation obtained by a least-square ﬁt.
TABLE 3 Results of multiple regression analysis














3 0.0054 (60.0010) 2.268 0.0043 2.368
25 0.069 (60.001) 1.161 0.158 0.800
2 0.970 (60.030) 0.013 0.497 0.303
9 1.200 (60.200) 0.079 1.680 0.225
7 5.000 (60.300) 0.699 3.820 0.582
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two components of the interaction energies in the ﬁve cases
analyzed here. As shown in Table 2, the maximum differ-
ence in the van der Waals interaction energy among the
inhibitors studied in this work is 16.9 kcal/mol, whereas in
the case of the electrostatic interaction energy this maximum
difference amounts up to 48.3 kcal/mol.
We have also tried to correlate LogIC50 versus DEelec or
DEVdW separately. The correlation coefﬁcients obtained are
signiﬁcantly worse, 0.89 and 0.82, respectively. This sug-
gests that correlations using only one of those components
are not sufﬁcient to describe the behavior of the inhibitors
within the CDK2 active site due to the important role that
each property has in the global interaction between the in-
hibitor and the amino acids at the active site. Instead of using
those descriptors separately, the whole interaction energy
(Eq. 5) or a multiple regression analysis with respect to both
terms (Eq. 6) can be used to predict the IC50 for a new
compound structurally related to the scaffold studied here in
a quantitative manner.
CONCLUSIONS
In this study we have demonstrated that the combined QM/
MMmethods provide a useful approximation to calculate the
interactions established at the CDK2 active site by a series
of compounds belonging to the N2-substituted-O6-cyclohex-
ylmethoxypurine family. This method allows us to describe
with some detail the nature of the speciﬁc interactions in-
volved in the protein-ligand binding. This fact makes the
method extensible to other groups of CDK2 inhibitory mole-
cules and, in fact, to other interesting biological systems.
Within the approach used here, it is further possible to obtain
an acceptable and representative picture of the real system in
which the evaluation of the different contributions from the
enzymatic and solvent environments to the protein-ligand
binding in the active site of the protein becomes a simpler
task. The consideration of ﬂexibility of almost the whole
protein and the ligand in the calculations performed with the
combined QM/MM methods allows us to achieve a wider
sampling of the conﬁgurational space. A huge set of possible
structures at a relevant temperature in the MD simulations
can be incorporated.
With respect to the speciﬁc interactions formed inside the
CDK2 active site by each of the compounds studied, we can
conclude that the enhanced potency observed for Nu6102
(Cp3) results from the hydrogen-bond interactions formed
between the sulfonamide group and residues Asp-86, Lys-89,
and Ile-10. There is an additional gain in potency that de-
pends on favorable packing between the aniline aromatic
ring and the hydrophobic surface in the CDK2 binding site. It
is worth mentioning that this is the ﬁrst time to our knowl-
edge that the interactions of a compound with Lys-89 are
reported.
The statistical validation of the proposed method was per-
formed by means of multiple regression analysis. This anal-
ysis allows us to conclude that there exists a high degree of
conﬁdence in the data presented for the calculated interaction
energy components of each inhibitor using the combined
QM/MM described before. Taking into account the values of
the two variables proposed and their correlation with the
biological activity values reported in the literature, it seems
possible to predict the IC50 value for a new compound. The
evaluation of the averaged interaction energies has allowed
us to show the strong correlation existing with the biological
activity of this series of inhibitors. In fact, the QM/MM inter-
action energy could be used as a predictor of the biological
activity, at least, within this family of compounds. The use
of QM/MM interaction energies has a double advantage: i)
extensive reparametrization of new ligands is avoided, and
ii) the computational effort is considerably smaller than for
the evaluation of binding free energies. Energy decomposi-
tion shows that in all compounds, except Cp3, the major
contribution to the total interaction energy is made by the van
der Waals energy component. In some compounds, the hy-
drogen bonds facilitate the interactions with the hydrophobic
surface of the enzyme.
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